Respiratory syncytial virus hospitalizations in healthy preterm infants

Pediatric Infectious Disease Journal

Volumn 35, Issue 7, 2016, Pages e229-e238

  Mauskopf, Josephine ^a   Margulis, Andrea V ^a   Samuel, Miny ^b   Lohr, Kathleen N ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

hospitalization; infectious disease; preterm infants; respiratory syncytial virus; risk factors

Indexed keywords

RIBAVIRIN; PALIVIZUMAB;

ANTIVIRAL THERAPY; ARTIFICIAL VENTILATION; BIOSIS; COCHRANE LIBRARY; CONSULTATION; DATA SYNTHESIS; DAY CARE; ECZEMA; EMBASE; GESTATIONAL AGE; HOSPITALIZATION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INCIDENCE; INFANT; LENGTH OF STAY; LONG TERM CARE; MEDLINE; ODDS RATIO; OUTCOME ASSESSMENT; PREMATURITY; PRIORITY JOURNAL; QUALITATIVE RESEARCH; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEASONAL VARIATION; SIBLING; SMALL FOR DATE INFANT; SYSTEMATIC REVIEW; VIRUS STRAIN; WHEEZING; INFANT, PREMATURE, DISEASES; ISOLATION AND PURIFICATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SEASON; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VIROLOGY;

GESTATIONAL AGE; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RISK FACTORS; SEASONS; TREATMENT OUTCOME;

EID: 84964402644     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001163     Document Type: Review

References (58)

1. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-Analysis. Lancet. 2010;375:1545-1555.
2. Winterstein AG, Knox CA, Kubilis P, et al. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study. JAMA Pediatr. 2013;167:1118-1124.
3. American Academy of Pediatrics (AAP) Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:415-420.
4. American Academy of Pediatrics (AAP) Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Technical report: updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:e620-e638.
5. Synagis (palivizumab) injection for intramuscular use [prescribing information]. March 2014. Available at: http://www.medimmune.com/docs/defaultsource/pdfs/prescribing-information-for-synagis.pdf. Accessed July 29, 2015.
6. Langley GF, Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J. 2011;30:510-517.
7. Resch B, Kurath S, Manzoni P. Epidemiology of respiratory syncytial virus infection in preterm infants. Open Microbiol J. 2011;5:135-143.
8. Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
9. Viswanathan M, Berkman ND, Dryden DM, Hartling L [web site]. Assessing risk of bias and confounding in observational studies of interventions or exposures: further development of the RTI Item Bank. Report No.: 13-EHC106-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2013. http://www.ncbi.nlm.nih.gov/books/NBK154461/. Accessed June 16, 2015.
10. Berkman ND, Lohr KN, Morgan LC, et al. Interrater reliability of grading strength of evidence varies with the complexity of the evidence in systematic reviews. J Clin Epidemiol. 2013;66:1105-1117.e1.
11. Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group. Casecontrol study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004;23:815-820.
12. Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23:806-814.
13. Figueras-Aloy J, Quero-Jiménez J, Fernández-Colomer B, et al; Grupo IRIS. [Usefulness of different risk factor associations in predicting admissions due to respiratory syncytial virus in premature newborns of 32 to 35 weeks gestation in Spain]. An Pediatr (Barc). 2009;71:47-53.
14. Carbonell X, Fullarton JR, Gooch KL, et al. The evolution of risk factors for respiratory syncytial virus-related hospitalisation in infants born at 32-35 weeks? gestational age: time-based analysis using data from the FLIP-2 study. J Perinat Med. 2012;40:685-691.
15. Blanken MO, Koffijberg H, Nibbelke EE, et al; Dutch RSV Neonatal Network. Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study. PLoS One. 2013;8:e59161.
16. Ambrose CS, Anderson EJ, Simões EA, et al. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J. 2014;33:576-582.
17. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537.
18. Joffe S, Escobar GJ, Black SB, et al. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics. 1999;104(4 Pt 1):894-899.
19. Stevens TP, Sinkin RA, Hall CB, et al. Respiratory syncytial virus and premature infants born at 32 weeks? gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 2000;154:55-61.
20. Wegner S, Vann JJ, Liu G, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Pediatrics. 2004;114:1612-1619.
21. Hampp C, Kauf TL, Saidi AS, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med. 2011;165:498-505.
22. Blanken MO, Rovers MM, Bont L; Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze. N Engl J Med. 2013;369:782-783.
23. Gouyon JB, Rozé JC, Guillermet-Fromentin C, et al. Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study Epidemiol Infect. 2013;141:816-826
24. Hsu CH, Lin CY, Chi H, et al. Prolonged seasonality of respiratory syncytial virus infection among preterm infants in a subtropical climate. PLoS One. 2014;9:e110166.
25. Meert K, Heidemann S, Lieh-Lai M, et al. Clinical characteristics of respiratory syncytial virus infections in healthy versus previously compromised host. Pediatr Pulmonol. 1989;7:167-170.
26. Meert K, Heidemann S, Abella B, et al. Does prematurity alter the course of respiratory syncytial virus infection?. Crit Care Med. 1990;18:1357-1359.
27. Navas L, Wang E, de Carvalho V, et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr. 1992;121:348-354.
28. Moler FW, Steinhart CM, Ohmit SE, et al. Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-Associated respiratory failure. Pediatric Critical Study Group. J Pediatr. 1996;128:422-428.
29. Law BJ, Wang EE, MacDonald N, et al. Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection?. An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database. Pediatrics. 1997;99:E7.
30. Dougherty NN, Meissner HC. Respiratory syncytial virus immunoprophylaxis: impact on epidemiology. Paediatr Drugs. 2000;2:127-132.
31. Prais D, Schonfeld T, Amir J; Israeli Respiratory Syncytial Virus Monitoring Group. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use. Pediatrics. 2003;112(3 pt 1):548-552.
32. Fodha I, Vabret A, Ghedira L, et al. Respiratory syncytial virus infections in hospitalized infants: association between viral load, virus subgroup, and disease severity. J Med Virol. 2007;79:1951-1958.
33. Sampalis JS. Morbidity and mortality after RSV-Associated hospitalizations among premature Canadian infants. J Pediatr. 2003;143(5 suppl):S150-S156.
34. Simoes EA, Groothuis JR, Carbonell-Estrany X, et al.; Palivizumab Long-Term Respiratory Outcomes Study Group. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007;151:34-42, 42.e1.
35. Palmer L, Hall CB, Katkin JP, et al. Healthcare costs within a year of respiratory syncytial virus among Medicaid infants. Pediatr Pulmonol. 2010;45:772-781.
36. Palmer L, Hall CB, Katkin JP, et al. Respiratory outcomes, utilization and costs 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infants. Curr Med Res Opin. 2011;27:403-412.
37. Fauroux B, Gouyon JB, Roze JC, et al. Respiratory morbidity of preterm infants of less than 33 weeks gestation without bronchopulmonary dysplasia: a 12-month follow-up of the CASTOR study cohort. Epidemiol Infect. 2014;142:1362-1374.
38. Ralston SL, Lieberthal AS, Meissner HC, et al; American Academy of Pediatrics. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134:e1474-e1502.
39. Thomsen SF, van der Sluis S, Stensballe LG, et al. Exploring the association between severe respiratory syncytial virus infection and asthma: a registrybased twin study. Am J Respir Crit Care Med. 2009;179:1091-1097.
40. Zomer-Kooijker K, Uiterwaal CS, van der Gugten AC, et al. Decreased lung function precedes severe respiratory syncytial virus infection and post-respiratory syncytial virus wheeze in term infants. Eur Respir J. 2014;44:666-674.
41. Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000;137:865-870.
42. Liese JG, Grill E, Fischer B, et al; Munich RSV Study Group. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr. 2003;162:230-236.
43. Nachman SA, Navaie-Waliser M, Qureshi MZ. Rehospitalization with respiratory syncytial virus after neonatal intensive care unit discharge: A 3-year follow-up. Pediatrics. 1997;100:E8.
44. Doering G, Gusenleitner W, Belohradsky BH, et al. The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks? gestational age. Pediatr Infect Dis J. 2006;25:1188-1190.
45. Clark SJ, Beresford MW, Subhedar NV, et al. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch Dis Child. 2000;83:313-316.
46. Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child. 2003;88:1065-1069.
47. Carbonell-Estrany X, Quero J, Bustos G, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J. 2000;19:592-597.
48. Carbonell-Estrany X, Quero J; IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J. 2001;20:874-879.
49. Heikkinen T, Valkonen H, Lehtonen L, et al. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch Dis Child Fetal Neonatal Ed. 2005;90(1):F64-F68.
50. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics. 1997;99(1):93-99.
51. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, et al; IRIS Study Group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J. 2003;22:823-827.
52. McCormick J, Tubman R. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit. Pediatr Pulmonol. 2002;34:262-266.
53. Singleton R, Dooley L, Bruden D, et al. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. Pediatr Infect Dis J. 2003;22:540-545.
54. Resch B, Pasnocht A, Gusenleitner W, et al. Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age. J Infect. 2005;50:397-403.
55. Resch B, Gusenleitner W, Müller WD, et al. Observational study of respiratory syncytial virus-Associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks. Eur J Clin Microbiol Infect Dis. 2006;25:120-122.
56. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, et al; IRIS Study Group. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008;27:788-793.
57. Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virusassociated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132:e341-e348.
58. Helfrich AM, Nylund CM, Eberly MD, et al. Healthy Late-preterm infants born 33-36+6 weeks gestational age have higher risk for respiratory syncytial virus hospitalization. Early Hum Dev. 2015;91:541-546.